Pfizer recalls mislabeled bottles of adult Robitussin

cough syrup on geometric table cloth

Pfizer's Consumer Healthcare is pulling tens of thousands of bottles of one of its adult Robitussin products in the U.S. due to a labeling issue. It comes just weeks after a different kind of manufacturing snafu led to the recall of its children's Advil products in Canada.

According to the most recent FDA Enforcement Report, Pfizer ($PFE) is voluntarily recalling 63,636 bottles of Adult Robitussin PEAK COLD Cough & Chest Congestion DM Liquid in 8-oz. bottles. The FDA report didn't give specifics, but according to a notice posted on the website of supermarket chain Wegmans, some of the PEAK COLD meds had been mislabeled as Adult Robitussin Maximum Strength Nighttime Cough DM. The recall began in February but was just posted this week by the FDA.

In February, Pfizer voluntarily recalled 126 lots of Children's Advil in Canada because "clumps" of the active ingredient ibuprofen could form in the bottle and lead to higher or lower doses given to infants and children if it the bottle was not shaken well before each use.

Free Webinar

Striving for Zero in Quality & Manufacturing

Pharmaceutical and medical device manufacturers strive towards a culture of zero – zero hazards, zero defects, and zero waste. This webinar will discuss the role that content management plays in pharmaceutical manufacturing to help companies reach the goal of zero in Quality and Manufacturing.

In that case, the New York-based drugmaker said it discovered the problem during routine stability testing and tracked the problem to a change to an emulsifying ingredient (xanthan gum) from one of Pfizer's suppliers that allowed ibuprofen in the liquid suspension to separate over time. It said it had replaced the source of that ingredient.

- find the Pfizer recall here
- here's the Wegmans notice

Read more on

Suggested Articles

Continuing its expansion efforts, Japan’s Fujifilm will make a major investment in its U.S. gene therapy operation in Texas.

Boehringer Ingelheim is investing $50 million in an animal health plant in Puerto Rico, adding 105 jobs.

Teva will begin producing chemo drug vincristine in the U.S. but has resisted the idea that its withdrawal from the market led to a shortage.